The erectile dysfunction treatment market consists of drugs and therapies used for improving erections and sexual performance in individuals suffering from erectile dysfunction. Some of the common erectile dysfunction treatments available in the market include phosphodiesterase type 5 inhibitors (PDE5 inhibitors), injections, implants, urethral suppositories, and penile rings. PDE5 inhibitors are one of the most popular and widely used drugs for ED treatment as they are non-invasive and have minimal side effects. Erectile dysfunction can affect both physical and mental health and reduce self-esteem, leading to anxiety and depression.
The global erectile dysfunction treatment market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing prevalence of erectile dysfunction represents a major market opportunity for erectile dysfunction treatment manufacturers. Erectile dysfunction incidence increases with age, affecting over 30 million men in the United States alone. By 2025, over 322 million men worldwide are expected to be affected by ED. With rising life expectancy and lifestyle diseases leading to higher risks of ED, the prevalence of the condition is poised to increase significantly in the coming years. The consistent rise in ED patients globally will drive greater uptake of drugs, devices, and therapies for effective erectile dysfunction treatment. In addition, growing awareness about available treatment options and willingness to seek medical help for improved sexual health will further boost demand for erectile dysfunction drugs and medications over the forecast period.
Porter's Analysis
Threat of new entrants: The erectile dysfunction treatment market requires high RD investments and obtainment of regulatory approvals which poses barriers for new players.
Bargaining power of buyers: Buyers have high bargaining power due to availability of generic and alternative treatment options.
Bargaining power of suppliers: Suppliers have moderate bargaining power owing to availability of substitutable raw materials.
Threat of new substitutes: herbal supplements and exercise-based treatment pose threat of substitution.
Competitive rivalry: The market is dominated by key players but witnessing high competition due to development of novel drug delivery systems.
SWOT Analysis
Strength: Availability of various drug classes for treatment and rising awareness for treatment options.
Weakness: Social stigma associated with the condition limits patients from seeking treatment and potential side-effects of drugs.
Opportunity: Increasing geriatric population who are at high risk of ED and growing adoption of minimally invasive therapies.
Threats: Patent expiries of blockbuster drugs and development of alternatives like mechanical devices.
Key Takeaways
The global erectile dysfunction treatment market is expected to witness high growth.
Regionally, North America dominates the market currently due to favorable reimbursement policies and high healthcare expenditure. Asia Pacific is poised to grow at the fastest pace due to rising cases of lifestyle diseases and growing medical tourism.
Key players operating in the erectile dysfunction treatment market are Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific, Cipla Ltd, Pfizer Inc., Coloplast CORP, Eli Lily Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC. Major players are focused on developing advanced drug delivery systems to expand their market share.
